In capecitabine manufacturing, 1,2,3-tri-O-acetyl-5-deoxy-D-ribofuranose (C₁₁H₁₆O₇, molecular weight 260.24 g/mol) is charged as the ribofuranose donor in a Vorbruggen silylation-Hilbert-Johnson coupling. Before charging, the reactor is inerted with nitrogen until the vent dew point is below −40 °C. The silylated 5-fluorocytosine is prepared separately by heating 5-fluorocytosine with hexamethyldisilazane and catalytic trimethylchlorosilane in dichloromethane at 40–45 °C for 4–6 h. The triacetate is dissolved in anhydrous dichloromethane and added to the silylated base at a base-to-donor molar ratio of 1.2:1 to 1.3:1. Tin(IV) chloride is then charged at 1.5–2.0 equivalents over 45–90 min with the reactor internal temperature held between −5 °C and +5 °C in a glass-lined reactor with jacket control tolerance of ±2 °C. The addition exotherm is removed through a condenser with outlet temperature maintained below −10 °C. After 3–5 h, in-process HPLC at 265 nm is used to confirm donor consumption below 1.0 % relative area. The reaction mass is quenched with cold 8 % sodium bicarbonate solution at 0–10 °C; the organic layer is washed with water and 5 % sodium chloride solution. Concentration under vacuum is performed below 40 °C. The resulting 2',3'-di-O-acetyl-5'-deoxy-5-fluorocytidine is treated with sodium methoxide in methanol at 20–25 °C for 3–5 h to cleave the acetyl groups. The pH is maintained between 7.5 and 8.5 with acetic acid. The deacetylated intermediate is isolated by crystallization from isopropanol/water. N4-pentyloxycarbonylation is then performed with n-pentyl chloroformate in pyridine/dichloromethane at 0–5 °C, followed by pH-adjusted precipitation. The terminal API is N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine, the active moiety in capecitabine tablets. The same intermediate specification for residual solvents supports the oral tablet route because acetonitrile, dichloromethane, and pyridine are controlled under ICH Q3C limits. Final tablet strengths of 150 mg and 500 mg are common; dissolution is controlled against USP <711> methods cited in the applicable monograph. The triacetate itself is not compressed into tablets; it is the upstream donor that determines the anomeric purity and residual solvent burden of the final drug substance.

Process deviations in the capecitabine route are most often traced to moisture ingress during the glycosylation step. If the reactor dew point is above −30 °C or the dichloromethane water content exceeds 0.05 %, the Lewis acid is partially hydrolyzed, and the coupling rate falls. The in-process HPLC method for the protected cytidine intermediate uses a short C18 column with 1.8 µm particle size, mobile phase acetonitrile/water with 0.1 % trifluoroacetic acid, column temperature 30 °C, and flow rate 1.0 mL/min. The α-anomer is controlled in the final API below 0.15 % area. Residual tin from tin(IV) chloride is monitored by ICP-MS. If the crude coupling mixture is left at ambient temperature for more than 12 h before quench, anomeric equilibration can increase the α-form and reduce yield. The terminal API is dried in an agitated vacuum filter-dryer at 35–40 °C until loss on drying is below 0.5 %.

How Is Doxifluridine Prepared from the Same 5-Deoxyribofuranose Donor?

The route diverges at the nucleobase. Silylated 5-fluorouracil is generated from 5-fluorouracil, hexamethyldisilazane, and trimethylchlorosilane in dichloromethane at 35–40 °C for 3–5 h. The silyl donor is coupled with the triacetate at a base-to-donor molar ratio of 1.1:1 to 1.3:1. Tin(IV) chloride is added at 1.5 equivalents in the same solvent at −10 °C to 0 °C. The glycosylation is performed in a glass-lined reactor equipped with a retreat-curve impeller; agitation speed is set at 80–120 rpm. After 2–4 h, the reaction mass is quenched into cold 10 % ammonium chloride solution. The organic phase is concentrated, redissolved in methanol, and treated with sodium methoxide at pH 8.0–8.5 for 3–6 h at 18–22 °C. Neutralization is performed with acetic acid or a weak acid ion-exchange resin. The product is extracted and crystallized from ethanol/water. The isolated compound is 5'-deoxy-5-fluorouridine, or doxifluridine. The typical capsule strength is 200 mg. The API is milled and classified, then blended with lactose monohydrate, croscarmellose sodium, and magnesium stearate before encapsulation. Disintegration is controlled according to USP <701> or the equivalent Japanese Pharmacopoeia chapter. Water content after vacuum drying at 40 °C for 12 h is maintained below 0.5 %. The same acceptor-position selectivity that applies to 5-fluorocytosine coupling also operates here: the 2-O-acetyl group directs the reaction toward the β-anomer, and the α-anomer must be monitored by HPLC at 254 nm because it can co-elute with the main peak on short C18 columns if the organic modifier is below 20 % acetonitrile.

Beyond the two commercial fluoropyrimidines, the triacetate functions as a glycosyl donor for modified purine and pyrimidine bases in early-stage nucleoside analogue discovery. The 5-deoxy modification is introduced at the sugar level because it eliminates the 5'-hydroxyl group and thereby prevents 5'-phosphorylation of the resulting nucleoside. This property alters kinase recognition and intracellular retention, which is relevant for candidate selection in oncology and antiviral programs. Coupling reactions are run on a 0.1–2.0 mol scale in jacketed glass reactors or parallel synthesizers. Silylated bases such as 2-amino-6-chloropurine, 6-chloropurine, 5-azacytosine, and 5-fluorouracil are condensed with the triacetate in acetonitrile or dichloromethane using trimethylsilyl trifluoromethanesulfonate or tin(IV) chloride at 0–25 °C. The 2-O-acetyl group directs β-glycoside formation. α-Anomer levels are monitored by reverse-phase HPLC with UV detection at 254 nm; for in vivo candidates the α-anomer is held below 2 % area. Deprotection is performed with methanolic ammonia at 20–25 °C for 12–18 h when base-labile protecting groups are present. The resulting modified nucleosides are isolated as lyophilized powders for in vitro metabolism assays and pharmacokinetic screening. Analytical release includes LC-MS purity above 98 % area and headspace gas chromatography for residual solvents according to Ph. Eur. 2.4.24. For preclinical injectable formulations, the lyophilized powder is reconstituted in Water for Injection and filtered through a 0.22 µm PVDF membrane. Subvisible particulates are checked against USP <788>. Published data for this specific configuration is limited for certain base variants; glycosylation yields must be confirmed experimentally rather than assumed from ribofuranose donor analogues.

Process safety during small-scale coupling campaigns is focused on the exothermic addition of trimethylsilyl trifluoromethanesulfonate. The reagent is charged via syringe pump at a rate that maintains the internal temperature at 0–25 °C. Aqueous quench is performed with 0.5 N sodium bicarbonate because stronger bases can hydrolyze the purine ring. The lyophilized nucleoside analogues are stored at −20 °C under argon for long-term stability. The use of the 5-deoxy donor in these libraries is not a substitute for full preformulation; each derivative must be evaluated for solubility, permeability, and solid-state form separately.

Residual Acetate Hydrolysis and Anomer Stability in Multi-Kilogram Campaigns

During storage and processing of 1,2,3-tri-O-acetyl-5-deoxy-D-ribofuranose, the anomeric acetate is the most labile ester. Hydrolysis occurs when the material is exposed to ambient moisture above 60 % RH or when drums are opened repeatedly outside nitrogen-purged zones. The free anomeric hydroxyl can undergo mutarotation and shift the α/β ratio before coupling. Batch-to-batch anomer ratio is controlled by proton NMR integration of the anomeric proton region; integration results are recorded at 400 MHz and reported as the β/α ratio rather than as a single chemical shift. When the β-anomer content falls below 85 %, the downstream Vorbruggen coupling shows a measurable drop in β-nucleoside yield and an increase in α-nucleoside impurity above 0.5 % area. The deacetylation step must distinguish between the three acetyl groups. Selective hydrolysis at C1 during aqueous work-up is avoided because the resulting diacetate can open to an aldehyde under basic conditions. The process window for methanolic deacetylation is pH 7.5–8.5, temperature 18–22 °C, and reaction time 3–6 h. Outside this window, acetyl migration and furanose ring opening create polar impurities that are difficult to purge without chromatography. In multi-kilogram campaigns, dichloromethane is stripped in a thin-film evaporator below 45 °C and 30 mbar. Agitated vacuum drying at 35–40 °C for 10–14 h reduces water content below 0.3 %. Drum filling is performed under nitrogen when residual acetic acid in the headspace exceeds 0.1 % v/v.

In a campaign where the triacetate is received as a liquid, the first operation is usually solvent exchange into dichloromethane. The transfer line is pre-dried with nitrogen and the receiving vessel is equipped with a moisture sensor. If the sensor reads above 0.5 g/kg in the solvent, molecular sieves are charged. The acetyl hydrolysis impurity is measured by gas chromatography on a polyethylene glycol column. The limit for the diacetate impurity is 0.5 % area, and for free 5-deoxy-D-ribofuranose it is 0.3 % area. Batches above these limits are subjected to mild re-acetylation with acetic anhydride in pyridine before release to the glycosylation step.

When Direct Compression Is Not Feasible for the Triacetate Itself

When formulation developers evaluate the triacetate as a direct-compression substrate, the limiting factor is not chemical stability but physical form. The material is typically a syrupy liquid or low-melting solid, and its bulk density is not suitable for high-speed tablet compression. Direct compression is therefore not performed with the triacetate itself. The intended downstream route is chemical: the triacetate is converted into a final API such as capecitabine or doxifluridine, and only the final API is formulated into tablet, capsule, granule, or injection dosage forms. For oral tablets, the final API is blended with microcrystalline cellulose, crospovidone, and lactose monohydrate; wet granulation or direct compression is chosen according to the final API particle size and flow function coefficient. For capsules, the final API is blended with pregelatinized starch and magnesium stearate before filling. Granule dosage forms are prepared by fluid-bed granulation with an aqueous or solvent-based binder; granule size distribution is verified by sieve analysis using Ph. Eur. 2.9.12. For injectables, the final API is processed through sterile filtration and lyophilization; the triacetate itself is not present. If an injectable-grade downstream API is required, the triacetate batch must meet ICH Q3D elemental impurity limits with particular attention to tin residues from Lewis acid catalysis. Residual tin is measured by ICP-MS and compared with the parenteral permitted daily exposure derived from ICH Q3D. When the found tin residue is above the qualified threshold, an additional purge step or a switch to trimethylsilyl trifluoromethanesulfonate catalysis is used.

The choice between tablet and capsule for the downstream API is determined by particle size, bulk density, and flow function coefficient. If the final API has a median particle size below 20 µm, direct compression may cause flow defects; wet granulation is preferred. If the final API is above 80 µm, capsule filling weight variation can be controlled by vibratory filling. The triacetate's own residual solvent profile influences the final purification burden because each solvent must be demonstrated to be purged to below the ICH Q3C limit before the drug product is released. For injectable campaigns, the downstream API is dissolved in Water for Injection, filtered through a 0.22 µm PVDF filter, and lyophilized in 10 mL or 20 mL capacity vials. The lyophilization cycle parameters are established by process development, not by the triacetate supplier.

Process validation for Class 2 residual solvent control across oral and injectable routes is driven by the difference in permitted daily exposure. Acetonitrile, dichloromethane, methanol, and pyridine are the main solvents tracked through the synthetic sequence. The triacetate release specification includes a gas chromatography headspace method based on Ph. Eur. 2.4.24 or USP <467> with flame ionization detection. The column is a 30 m × 0.32 mm × 1.8 µm 6 % cyanopropylphenyl/94 % dimethylpolysiloxane capillary column. The oven is programmed from 40 °C to 220 °C at 10 °C/min; injector temperature is 200 °C and split ratio is 20:1. Limits of quantitation are typically 20 ppm for acetonitrile, 30 ppm for dichloromethane, and 50 ppm for methanol. The acceptance limits are derived from ICH Q3C Table 2 and adjusted for a 10-fold purge factor during downstream processing. Batches failing the residual solvent specification are re-dried in an agitated vacuum dryer at 35–40 °C for 6–12 h under nitrogen sweep. Re-drying is revalidated for injectable campaigns because the parenteral finished product has a lower allowable solvent load than oral tablets.

Solid-State Storage and Logistics Parameters Determine Downstream Batch Purity

The physical stability of 1,2,3-tri-O-acetyl-5-deoxy-D-ribofuranose under international transport conditions affects the quality of the downstream batch. The compound is packed in sealed epoxy-phenolic-lined steel drums or high-density polyethylene drums with nitrogen overlay. Storage conditions are 2–8 °C with relative humidity below 50 %. At temperatures above 25 °C, the anomeric acetate undergoes slow hydrolysis even in closed containers if the headspace dew point is above −20 °C. The acceptance specification for assay by HPLC is 98.0–102.0 % area, and moisture content is controlled below 0.2 %. Accelerated condition risk assessment at 25 °C ± 2 °C and 60 % RH ± 5 % identifies anomer hydrolysis as the primary degradation pathway; the expected degradation products are 2,3-di-O-acetyl-5-deoxy-D-ribofuranose and free 5-deoxy-D-ribofuranose. Both are controlled by HPLC at relative retention times characterized during analytical method validation. If the triacetate is shipped in refrigerated containers, the container air-handling unit must not introduce condensation during door openings. Pallets are wrapped with vapor barrier film and silica gel desiccant units of 1 kg per cubic metre. Before charging to the reactor, the material is equilibrated to 20–25 °C under nitrogen. The receiving batch record records drum headspace oxygen below 2 % and dew point below −30 °C. These controls are part of the vendor assurance program under ISO 15378:2017 and are reviewed during supplier audits. Published stability data for the exact triacetate stored in unopened commercial containers is limited; therefore, site-specific bracketing studies according to ICH Q1A(R2) are used to justify the storage statement.

Analytical method transfer for the triacetate includes forced degradation studies under acidic, basic, oxidative, and thermal stress. The stability-indicating method uses a C18 column with UV detection at 210 nm. Acidic stress with 0.1 N hydrochloric acid at 25 °C for 24 h produces the deacetylated impurity; basic stress with 0.1 N sodium hydroxide produces furanose ring-opening products. Oxidative stress with 3 % hydrogen peroxide may increase the peroxide value. The method is validated for specificity, linearity, accuracy, precision, and quantitation limit according to ICH Q2(R2) or ICH Q14. These data support the application dossier for downstream capecitabine and doxifluridine manufacturers.